Trusted Resources: Education
Scientific literature and patient education texts
Development of the SMA Independence Scale-Upper Limb Module (SMAIS-ULM): A Novel Scale for Individuals With Type 2 and Non-Ambulant Type 3 SMA
source: Journal of the neurological sciences
year: 2022
authors: Trundell D,Skalicky A,Staunton H,Hareendran A,Le Scouiller S,Barrett L,Cooper O,Gorni K,Seabrook T,Jethwa S,Cano S
summary/abstract:Background: The amount of assistance required to perform daily activities for individuals with Type 2 and non-ambulant Type 3 spinal muscular atrophy (SMA) is often cited as meaningful for quality of life, and important to routinely assess.
Methods: The SMA Independence Scale (SMAIS), a patient-reported outcome measure for individuals with SMA aged ≥12 years, and an observer-reported outcome measure for caregivers of individuals aged ≥2 years, was developed and evaluated in two phases. In Phase 1, 30 draft items were developed following review of the literature. Semi-structured interviews were then conducted with individuals with SMA and caregivers to establish content validity, resulting in a 29-item measure. In Phase 2, classical test theory and Rasch measurement theory methods were used to examine the cross-sectional and longitudinal measurement performance of the SMAIS in two independent datasets.
Results: Phase 1 qualitative findings supported the relevance, acceptability, and comprehensibility of 29 items. In Phase 2, psychometric analyses indicated that the five response options were poorly discriminated and were thus collapsed to three options for subsequent analyses. Items showed statistical misfit, implying that the SMAIS was not assessing a single underlying construct. Based on conceptual evaluation of the items, and assessment of item performance, a more targeted 22-item upper limb score was derived. Reliability and validity analyses confirmed acceptable measurement properties of this score.
Conclusions: Qualitative and quantitative analyses support the use of the 22-item SMAIS-Upper Limb Module in individuals with Type 2 and non-ambulant Type 3 SMA, aged ≥2 years.
organization: Roche Products Ltd, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK. Electronic address: [email protected].DOI: 10.1016/j.jns.2021.120059
read more
Related Content
-
Caregivers Need Information About Help With Future Care, Study FindsCaregivers of children with spinal muscu...
-
2023 Annual SMA ConferenceThe 2023 Annual SMA Conference will be h...
-
Mothers Want to Improve Children’s Quality of LifeMothers of children and adolescents with...
-
Epidemiology, Healthcare Resource Utilization and Healthcare Costs for Spinal Muscular Atrophy in Alberta, CanadaAims: Spinal muscular atrophy (SMA) is a...
-
General Guidelines for People With Spinal Muscular Atrophy or SMA and Their Caregivers in the Coronavirus Pandemichttps://wecarejourney.org/clients/We_Car...
-
Systematic Literature Review to Assess the Cost and Resource Use Associated With Spinal Muscular Atrophy ManagementSpinal muscular atrophy (SMA) is a sever...
-
Together in SMA – InstagramTogether in SMA, brought to you by Bioge...